Deepak Bhatt, MD, MPH, MBA, spoke to Cardiovascular Business about the growing importance of evaluating coronary inflammation in heart patients. There has been an explosion of interest in this area since the FDA's 2023 clearance of colchicine.
Hadley Wilson, MD, spoke to Cardiovascular Business at the three-day event to discuss key late-breaking studies and trends. Topics included new drug treatments, AI and much more.
Gilbert Tang, MD, spoke to Cardiovascular Business about late-breaking data from the TRILUMINATE IDE trial. While early results were promising, these latest findings highlight the TriClip device's true value for the first time.
Paul Sorajja, MD, discusses the late-breaking TRILUMINATE pivotal trial at ACC.23 and how tricuspid TEER performed against the current standard of care using medical therapy.
New research presented at the American College of Cardiology’s annual meeting has shown that long-term intermittent fasting improved outcomes for individuals with COVID-19 who also have a history of heart disease.
For patients who were hospitalized, but not yet in the ICU, those randomly assigned a higher-dose of anticoagulants had lower 30-day mortality risk than those on a lower dose.
Many patients who would clearly benefit by lowered LDL cholesterol levels are choosing to forgo first-time recommendations for statin regimens, according to a population-level study.
Some SGLT2 inhibitors have been linked to significant improvements in HF outcomes, but what about sotagliflozin? We spoke with Bertram Pitt, MD, to learn more.
Patients who are vaccinated at the time of their COVID-19 diagnosis appear to face a lower risk of new-onset type 2 diabetes than patients who are not vaccinated.
Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.
